Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Research & Development (2022 - 2025)

Historic Research & Development for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $587279.0.

  • Coeptis Therapeutics Holdings' Research & Development fell 2765.58% to $587279.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 5641.06%. This contributed to the annual value of $2.3 million for FY2024, which is 6503.51% down from last year.
  • Coeptis Therapeutics Holdings' Research & Development amounted to $587279.0 in Q3 2025, which was down 2765.58% from $290309.0 recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' 5-year Research & Development high stood at $5.1 million for Q3 2023, and its period low was $20887.0 during Q3 2022.
  • Its 4-year average for Research & Development is $832077.2, with a median of $432723.0 in 2023.
  • In the last 5 years, Coeptis Therapeutics Holdings' Research & Development skyrocketed by 2418753.77% in 2023 and then crashed by 8884.8% in 2025.
  • Quarter analysis of 4 years shows Coeptis Therapeutics Holdings' Research & Development stood at $20887.0 in 2022, then skyrocketed by 4751.57% to $1.0 million in 2023, then crashed by 66.07% to $343878.0 in 2024, then skyrocketed by 70.78% to $587279.0 in 2025.
  • Its Research & Development stands at $587279.0 for Q3 2025, versus $290309.0 for Q2 2025 and $86659.0 for Q1 2025.